Keymed Biosciences (HKG:2162) unit Keymed Biosciences (Chengdu) has agreed to grant Platina Medicines the exclusive right to develop, manufacture, and commercialize CM336 globally, excluding Mainland China, Hong Kong, Macau, and Taiwan, a Nov. 17 bourse filing said.
The drug company will receive an upfront and near-term payment of $16 million under the contract and a minority equity interest in Delaware-incorporated Ouro Medicines, the parent company of Platina Medicines.
The firm may also receive additional milestone payments of up to $610 million, as well as tiered royalties on net sales of the drug and related products.
Under the agreement, UK-incorporated Platina Medicines will also source clinical supply of CM336 from Keymed Biosciences.
CM336 is a bispecific antibody used to treat patients with relapsed or refractory multiple myeloma.
Shares of the company were up nearly 2% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。